Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders

Christopher J. McDougle, Kimberly A. Stigler, Craig A. Erickson, David J. Posey

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Atypical antipsychotics are emerging as the first-line pharmacologic treatment for irritability (i.e., aggression, self-injurious behavior, and severe tantrums) in children and adolescents with autistic and other pervasive developmental disorders. Results from placebo-controlled and open-label studies of clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole in this subject population are reviewed. Additional placebo-controlled trials and studies of longer-term safety and tolerability are needed.

Original languageEnglish
Pages (from-to)15-20
Number of pages6
JournalJournal of Clinical Psychiatry
Volume69
Issue numberSUPPL. 4
StatePublished - 2008

Fingerprint

olanzapine
Antipsychotic Agents
Placebos
Self-Injurious Behavior
Risperidone
Clozapine
Aggression
Safety
Population
Therapeutics
Aripiprazole
Quetiapine Fumarate
ziprasidone

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Medicine(all)

Cite this

McDougle, C. J., Stigler, K. A., Erickson, C. A., & Posey, D. J. (2008). Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. Journal of Clinical Psychiatry, 69(SUPPL. 4), 15-20.

Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. / McDougle, Christopher J.; Stigler, Kimberly A.; Erickson, Craig A.; Posey, David J.

In: Journal of Clinical Psychiatry, Vol. 69, No. SUPPL. 4, 2008, p. 15-20.

Research output: Contribution to journalArticle

McDougle, CJ, Stigler, KA, Erickson, CA & Posey, DJ 2008, 'Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders', Journal of Clinical Psychiatry, vol. 69, no. SUPPL. 4, pp. 15-20.
McDougle, Christopher J. ; Stigler, Kimberly A. ; Erickson, Craig A. ; Posey, David J. / Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. In: Journal of Clinical Psychiatry. 2008 ; Vol. 69, No. SUPPL. 4. pp. 15-20.
@article{6e3fff18c2e34b589e6275cdc51ffec6,
title = "Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders",
abstract = "Atypical antipsychotics are emerging as the first-line pharmacologic treatment for irritability (i.e., aggression, self-injurious behavior, and severe tantrums) in children and adolescents with autistic and other pervasive developmental disorders. Results from placebo-controlled and open-label studies of clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole in this subject population are reviewed. Additional placebo-controlled trials and studies of longer-term safety and tolerability are needed.",
author = "McDougle, {Christopher J.} and Stigler, {Kimberly A.} and Erickson, {Craig A.} and Posey, {David J.}",
year = "2008",
language = "English",
volume = "69",
pages = "15--20",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders

AU - McDougle, Christopher J.

AU - Stigler, Kimberly A.

AU - Erickson, Craig A.

AU - Posey, David J.

PY - 2008

Y1 - 2008

N2 - Atypical antipsychotics are emerging as the first-line pharmacologic treatment for irritability (i.e., aggression, self-injurious behavior, and severe tantrums) in children and adolescents with autistic and other pervasive developmental disorders. Results from placebo-controlled and open-label studies of clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole in this subject population are reviewed. Additional placebo-controlled trials and studies of longer-term safety and tolerability are needed.

AB - Atypical antipsychotics are emerging as the first-line pharmacologic treatment for irritability (i.e., aggression, self-injurious behavior, and severe tantrums) in children and adolescents with autistic and other pervasive developmental disorders. Results from placebo-controlled and open-label studies of clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole in this subject population are reviewed. Additional placebo-controlled trials and studies of longer-term safety and tolerability are needed.

UR - http://www.scopus.com/inward/record.url?scp=46649086988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46649086988&partnerID=8YFLogxK

M3 - Article

C2 - 18533764

AN - SCOPUS:46649086988

VL - 69

SP - 15

EP - 20

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - SUPPL. 4

ER -